secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001193125-24-229453
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharmaceuticals Chapter 11 liquidation plan effective; common stock cancelled
--------------------------------------------------------------------------------

- September 30, 2024 effective date: all outstanding common shares cancelled and no longer valid.
- Equity holders entitled to pro rata share of Existing Equity Interest Recovery Pool, if any.
- Company intends to file Form 15 to immediately suspend SEC reporting obligations.
- Plan confirmed by Bankruptcy Court on September 5, 2024; earlier Chapter 11 filing on April 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524229453/0001193125-24-229453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524229453/d850551d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-229453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer